• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Lamictal (lamotrigine) Tablets and Lamisil (terbinafine hydrochloride) Tablets

This is a revised version of the June letter. This letter has: an "Important Drug Warning" boxed header, current MedWatch information and a July date. All other information is the same.

[July 2000 - Letter - Glaxo Wellcome, Inc.]

Health professionals, especially pharmacists, are notified of prescription dispensing errors involving Lamictal Tablets and Lamisil Tablets resulting in serious adverse events. The error reports involve dispensing Lamictal Tablets when Lamisil Tablets were prescribed and the reverse scenario.

[August 2000 - Health Professional Letter - Glaxo Wellcome, Inc.]
[August 2000 - Health Professional Letter PDF Format - Glaxo Wellcome, Inc.]
[June 6, 2000 - Pharmacist Letter - Glaxo Wellcome, Inc.]